Witness iBreastExam LIVE Demo
Engage with our Leadership Team
Explore Partnerships & Collaborations
As per the last WCC meeting, the #1 Participant's Area of Interest is "innovation in prevention, early detection & screening" - that's iBreastExam!
- Matthew Campisi, Co-Founder & CTO, UE LifeSciences
World Cancer Congress 2018
The World Cancer Congress (WCC) is a recognised international conference which encourages effective knowledge transfer and best practices exchange amongst 3,500 cancer control and public health experts from 150 countries.
It aims to strengthen the participants' action and impact on national, regional and international scales through a multidisciplinary programme that features the latest successful interventions in cancer prevention, diagnosis, treatment and care.
The World Cancer Congress is an initiative of the Union for International Cancer Control (UICC) - which was recognised with Membership Engagement Award - and supports the organisation's purpose statement 'to unite the cancer community, reduce the global cancer burden, promote greater equity and integrate cancer into the world's health and development agenda'.
Meet us at the WCC. Booth# E34
UE LifeSciences delegation to WCC 2018:
- Professor Matthew Campisi, Co-Founder & CTO
- Madhu Kumar, CEO, ASEAN
- Dr. Rohan Khandelwal (Medical Director) and
- Akshat Shah, Head Global Business Development
We're keen to meet with the key stakeholders - Cancer Societies, NGOs, Governmental Healthcare Agencies and Private Healthcare Providers - for whom early detection of breast cancer and pre-screening is a high priority.
UE LifeSciences & iBreastExam
UE LifeSciences (UELS) is a US based medical technology innovation company working to bring affordable, socially acceptable and clinically effective access to early detection of breast cancer for 1 billion women worldwide.
iBreastExam (iBE), UELS’ flagship innovation, is a hand-held, radiation-free device operable by lay health workers for early detection of breast lumps at the point-of-care. Over 150,000 women have received the test in 12 countries. With promising results, iBE is clinically validated in USA, India, Brazil and Mexico in well over 10,000 women. With US FDA clearance, CE mark and other regulatory approvals, iBE is now commercially available and scaling in over 10 countries.
Using patented tactile sensor technology developed at Drexel University, for the first-time, women in the developing world have access to a safe, affordable, painless and standardized breast examination. The device is equally effective in younger women and women with dense breasts. iBE has won several coveted innovation awards and grants, including the Bayer and Pfizer Foundation grants, has been featured in the New York Times, BBC News and TED Talks.
World Cancer Congress 2018
Kuala Lumpur Convention Center
Oct 1 - 4